Empreses emergents
2023
D-SIGHT SLTractaments revolucionaris per a malalties neurodegeneratives de la retina. Solució pionera per a la prevenció i el tractament de les etapes inicials de la retinopatia diabètica.
Adreça
Carrer de la Vall d'Hebron, 08035 Barcelona, Espanya
Dades financeres
Propietat CERCA
Barcelona, Spain
2002
Vall d’Hebron Institut de Recerca (VHIR)
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
D-Sight is founded and lead by world leaders in diabetic retinopathy, diabetes and other neurodegenerative diseases linked to the retina.
Value proposition
Efficacy: IN THE PREVENTION AND TREATMENT OF EARLY STAGES OF DIABETIC RETINOPATHY, WITH NO ASSOCIATED SIDE-EFFECTS.
Administration: OUR SOLUTION IS NON-INVASIVE AND SELF-ADMINISTRABLE.
Strong IP strategy: OUR PATENT FAMILY IS PRESENT IN 22 COUNTRIES WORLDWIDE.
Cost-effective: OUR TREATMENT IS CHEAPER THAN OTHER AVAILABLE THERAPIES, REPRESENTING A COST-SAVING SOLUTION FOR NATIONAL HEALTHCARE SYSTEMS IN THE WORLD.
Value proposition
Efficacy: IN THE PREVENTION AND TREATMENT OF EARLY STAGES OF DIABETIC RETINOPATHY, WITH NO ASSOCIATED SIDE-EFFECTS.
Administration: OUR SOLUTION IS NON-INVASIVE AND SELF-ADMINISTRABLE.
Strong IP strategy: OUR PATENT FAMILY IS PRESENT IN 22 COUNTRIES WORLDWIDE.
Cost-effective: OUR TREATMENT IS CHEAPER THAN OTHER AVAILABLE THERAPIES, REPRESENTING A COST-SAVING SOLUTION FOR NATIONAL HEALTHCARE SYSTEMS IN THE WORLD.
Descripció del producte
Improving the quality of life of diabetic patients
We have developed a first-in-class solution for the prevention and treatment of early stages of diabetic retinopathy.
D-Sight addresses a wide-spread unmet medical need with a cost-effective, non-invasive and safe treatment, which also prevents side-effects and limitations associated to current standard-of-care therapies.
Solution
D-Sight has developed a new innovative therapeutic approach for the prevention and treatment of early stages of diabetic retinopathy based on the topical ocular administration of DPP-IV inhibitors.
Our solution prevents neurodegeneration and the early microvascular alterations linked to these early stages of the disease.
We have developed a first-in-class solution for the prevention and treatment of early stages of diabetic retinopathy.
D-Sight addresses a wide-spread unmet medical need with a cost-effective, non-invasive and safe treatment, which also prevents side-effects and limitations associated to current standard-of-care therapies.
Solution
D-Sight has developed a new innovative therapeutic approach for the prevention and treatment of early stages of diabetic retinopathy based on the topical ocular administration of DPP-IV inhibitors.
Our solution prevents neurodegeneration and the early microvascular alterations linked to these early stages of the disease.